Amgen (AMGN) Non Operating Income (2009 - 2026)

Amgen's Non Operating Income history runs 18 years deep, the most recent figure standing at $75.0 million for Q1 2026.

• In Q1 2026, Non Operating Income fell 95.06% year-over-year to $75.0 million; the TTM figure through Mar 2026 stood at $1.2 billion (down 46.53% YoY), while the FY2025 annual figure was $2.7 billion, up 423.91% from the prior year.
• Non Operating Income was $75.0 million for Q1 2026 at Amgen, up from -$553.0 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $2.1 billion in Q3 2025 to a low of -$782.0 million in Q4 2024.
• Historically, Non Operating Income has averaged $308.9 million across 5 years, with a median of -$67.0 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Non Operating Income sank 4176.92% in 2022, then surged 745.96% in 2025.
• A 5-year view of Non Operating Income shows it stood at -$67.0 million in 2022, then surged by 700.0% to $402.0 million in 2023, then sank by 294.53% to -$782.0 million in 2024, then rose by 29.28% to -$553.0 million in 2025, then jumped by 113.56% to $75.0 million in 2026.
• The last three Non Operating Income figures came in at $75.0 million (Q1 2026), -$553.0 million (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.